Prosensa Holding Q3 Loss Widens - Quick Facts

(RTTNews) - Prosensa Holding N.V. (RNA), a biopharmaceutical company focusing on RNA-modulating therapeutics for rare diseases with high unmet need, Monday said net loss for the third quarter was 10.6 million euros, or 0.29 euro per share, compared to a net loss of 4.3 million euros, or 0.12 euro per share for the third quarter 2013.

Revenue was nil, compared with 2.4 million euros last year, due to a decrease in license revenue of 1.3 million euros and a decrease in collaboration revenue of 1.1 million euros due to the termination of the research and collaboration agreement with GSK.

Hans Schikan, CEO, said, "We are incredibly pleased with the substantial progress we have accomplished during this period. We have delivered on our promise of initiating the re-dosing process for patients who were previously in drisapersen clinical trials with a total of 15 boys now back on treatment, and our rolling New Drug Application (NDA) submission with the US Food & Drug Administration (FDA) is currently well underway."